Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin

We developed previously a resistant cell line, CEM/C2, from the human leukemia cell line CCRF-CEM by stepwise selection in camptothecin. This cell line is 974-fold more resistant to camptothecin than parental cells. Resistance is only partially explained by 2-fold reductions in topoisomerase I prote...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer research (Chicago, Ill.) Ill.), 1995-03, Vol.55 (6), p.1339-1346
Hauptverfasser:	FUJIMORI, A, HARKER, W. G, KOHLHAGEN, G, HOKI, Y, POMMIER, Y
Format:	Artikel
Sprache:	eng
Schlagworte:	Amino Acid Sequence Animals Antineoplastic agents Base Sequence Biological and medical sciences Camptothecin - pharmacology Cricetinae Cricetulus DNA Topoisomerases, Type I - genetics DNA Topoisomerases, Type I - metabolism Drug Resistance General aspects Humans Leukemia - drug therapy Leukemia - enzymology Leukemia - pathology Medical sciences Molecular Sequence Data Pharmacology. Drug treatments Point Mutation Recombinant Proteins - pharmacology Tumor Cells, Cultured
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!